Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertellus specialties expands in China
NRCC, which was established in 1998, has been operated by Vertellus as a joint venture with the Nantong Acetic Acid Chemical Corporation (NAACC). Sole control of the facility
NRCC, which was established in 1998, has been operated by Vertellus as a joint venture with the Nantong Acetic Acid Chemical Corporation (NAACC). Sole control of the facility
In addition to the three new collaborations, Adimab has also reached a technical milestone in its ongoing collaboration with Novartis, which was initiated in June of 2010. Under
The pilot study will enroll 20 patients with existing chronic wounds, who will be monitored over a 42-day period in order to evaluate the effectiveness of dCELL Human
The foundation will now support the development of the PD01 vaccine by AFFiRiS with $475,000. AFFiRiS said that the vaccine PD01 targets the protein known as alpha-synuclein (alpha-syn),
The goal of the project is to develop high affinity and renewable reagents to capture tryptic peptides derived from human plasma protein biomarkers, and then use the captured
As per the terms of the acquisition, Atrium acquired Minami for a total cash consideration of EUR5.5m ($7.38m) before a revenue earn-out payment of up to EUR2m ($2.68m)
As per the agreement, Merck will provide BioPontis Alliance with guidance on Merck product portfolio priorities, thereby ensuring alignment of market demand with the discovery science that BioPontis
The aim of the collaboration is to develop a new class of medication with a novel mechanism of action for the treatment of pain and inflammatory diseases. The
The study was designed to evaluate the safety and immunomodulatory effects of SCV-07 as a monotherapy and in combination with ribavirin in relapsed HCV patients. The study results
CEL-SCI claims that Multikine is its immunotherapy developed as a first-line standard of care in treating head and neck cancer. The Phase III trial will be run at